Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene |
|
https://doi.org/10.18632/oncotarget.27154
Tibor Bedekovics,
Sajjad Hussain,
and Paul J. Galardy
|
| 5124-5125 |
Ras functional proximity proteomics establishes mTORC2 as new direct ras effector
Ras functional proximity proteomics establishes mTORC2 as new direct ras effector |
|
https://doi.org/10.18632/oncotarget.27025
Joanna R. Kovalski,
Ronald L. Shanderson,
and Paul A. Khavari
|
| 5126-5135 |
Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma
Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma |
|
https://doi.org/10.18632/oncotarget.27098
Luís Alberto de Pádua Covas Lage,
Débora Levy,
Flávia Dias Xavier,
Diego Cândido Reis,
Renata de Oliveira Costa,
Marianne Castro Gonçalves,
Vanderson Rocha,
Maria Cláudia Nogueira Zerbini,
and Juliana Pereira
|
| 5136-5151 |
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model |
|
https://doi.org/10.18632/oncotarget.27114
Takeshi Jimbo,
Mana Hatanaka,
Takahiro Komatsu,
Tomoe Taira,
Kentaro Kumazawa,
Naoyuki Maeda,
Takashi Suzuki,
Masahiro Ota,
Noriyasu Haginoya,
Takeshi Isoyama,
and Kosaku Fujiwara
|
| 5152-5167 |
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A
Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A |
|
https://doi.org/10.18632/oncotarget.27125
Jennifer Bourn,
Sony Pandey,
Jashim Uddin,
Lawrence Marnett,
and Maria Cekanova
|
| 5168-5180 |
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay |
|
https://doi.org/10.18632/oncotarget.27142
Sarabjot Pabla,
Jonathan Andreas,
Felicia L. Lenzo,
Blake Burgher,
Jacob Hagen,
Vincent Giamo,
Mary K. Nesline,
Yirong Wang,
Mark Gardner,
Jeffrey M. Conroy,
Antonios Papanicolau-Sengos,
Carl Morrison,
and Sean T. Glenn
|
| 5181-5193 |
Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma
Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.27146
Catrin Tauber,
Michael Schultheiss,
Raffaele De Luca,
Nico Buettner,
Sian Llewellyn-Lacey,
Florian Emmerich,
Sebastian Zehe,
David A. Price,
Christoph Neumann-Haefelin,
Annette Schmitt-Graeff,
Maike Hofmann,
and Robert Thimme
|
| 5194-5206 |
Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy
Urodynamic outcomes after pelvic nerve-sparing radical hysterectomy with or without neoadjuvant chemotherapy |
|
https://doi.org/10.18632/oncotarget.27147
Satoshi Tsunetoh,
Yoshito Terai,
Masaaki Takai,
Satoe Fujiwara,
Yoshimichi Tanaka,
Tomohito Tanaka,
Hiroshi Sasaki,
Naokazu Ibuki,
Takanobu Ubai,
Kazuhiro Yamamoto,
Haruhito Azuma,
and Masahide Ohmichi
|
| 5207-5216 |
Increased expression of cathepsin D is required for L1-mediated colon cancer progression
Increased expression of cathepsin D is required for L1-mediated colon cancer progression |
|
https://doi.org/10.18632/oncotarget.27155
Sayon Basu,
Sanith Cheriyamundath,
Nancy Gavert,
Thomas Brabletz,
Gal Haase,
and Avri Ben-Ze’ev
|
| 5217-5228 |
Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma
Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.27156
Jennifer Bryant,
Nikolaos Batis,
Anna Clara Franke,
Gabriella Clancey,
Margaret Hartley,
Gordon Ryan,
Jill Brooks,
Andrew D. Southam,
Nicholas Barnes,
Joanna Parish,
Sally Roberts,
Farhat Khanim,
Rachel Spruce,
and Hisham Mehanna
|
| 5229-5244 |
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database |
|
https://doi.org/10.18632/oncotarget.24703
Jie Zhang,
Xiao-Xiao Wang,
Jun-Yu Lian,
and Chuan-Gui Song
|
| 5245-5252 |
Correction: Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer
Correction: Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer |
|
https://doi.org/10.18632/oncotarget.27174
Yang Jin,
Zilian Cui,
Xudong Li,
Xunbo Jin,
and Jian Peng
|
| 5253-5253 |
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory |
|
https://doi.org/10.18632/oncotarget.27176
Natalia Paez Arango,
Lauren Brusco,
Kenna R. Mills Shaw,
Ken Chen,
Agda Karina Eterovic,
Vijaykumar Holla,
Amber Johnson,
Beate Litzenburger,
Yekaterina B. Khotskaya,
Nora Sanchez,
Ann Bailey,
Xiaofeng Zheng,
Chacha Horombe,
Scott Kopetz,
Carol J. Farhangfar,
Mark Routbort,
Russell Broaddus,
Elmer V. Bernstam,
John Mendelsohn,
Gordon B. Mills,
and Funda Meric-Bernstam
|
| 5254-5254 |
